COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #110
Source   PDF   Share   Tweet
See all 181 studies
Late treatment study
Catteau et al., Int. J. Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106144 (Peer Reviewed)
Low-dose Hydroxych loroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants
Retrospective 8,075 hospitalized patients, 4,542 low-dose HC Q, 3,533 control. 35% lower mortality for HC Q (17.7% vs. 27.1%), adjusted HR 0.68 [0.62–0.76]. Low-dose HC Q monotherapy was independently associated with lower mortality in hospitalized patients.
Patients exposed to others therapies (TCZ, AZ, LPV/RTV) were excluded.
Statistical analysis was performed by an independent group. Calendar time of prescription and immortal time bias was taken into account. Corticosteroids prescriptions was low in both groups.
death, ↓32.0%, p<0.0001
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.